<PAGE> 1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT - April 29, 1997
(Date of Earliest Event Reported)
Nu-Tech Bio-Med, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-11772 25-1411971
---------------------------- ---------------- ---------------
State or Other Jurisdiction (Commission File (I.R.S. Employer
of Incorporation) Number) Identification No.)
55 Access Road
Warwick, Rhode Island 02886
---------------------------
(Address of Principal Executive Offices)
Registrant's telephone number, including area code: (401) 732-6520
--------------------
================================================================================
<PAGE> 2
Item 5. Other Events.
- ----------------------
On April 29, 1997, Nu-Tech Bio-Med, Inc. (the "Company") reduced the
exercise price of 1,076,979 warrants (the "Warrants") and 15,856 options (the
"Options"), respectively, to $1.76 per share, which price is equal to 75% of the
average closing price for the Company's common stock for the ten (10) days prior
to such reduction. Upon the expiration of the 45 day period following such
exercise price reduction, the option and/or warrant exercise price of the
Options and the Warrants will revert to and be exercisable at their original
respective exercise prices which range from $4.35 per share to $28.35 per share.
None of the Options and the Warrants are directly or indirectly owned by any
officer or director of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
----------------------------------------
Name: J. Marvin Feigenbaum
Title: Chairman of the Board, President,
Chief Executive and Chief
Financial Officer
Date: May 1, 1997
